Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised evaluation of molecular guided therapy for diffuse large B-cell lymphoma with Bortezomib

Trial Profile

A randomised evaluation of molecular guided therapy for diffuse large B-cell lymphoma with Bortezomib

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Acronyms REMoDL-B
  • Most Recent Events

    • 13 Dec 2022 Results (n=67) assessing the impact of R-CHOP on QoL in patients enrolled in the control arm of the study, with 5 years of follow-up, presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 01 Apr 2019 Results evaluating outcomes of adding bortezomib to standard therapy in patients with diffuse large B-cell lymphoma published in the Lancet Oncology
    • 03 Dec 2018 Results of retrospective study from patients (n=928) treated in REMoDL-B trial, published in the Journal of Clinical Oncology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top